
Proceedings of the WFH’s Eleventh Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which

This resource has also been translated into the following languages, with permission from the WFH, by NMOs/Other Organizations: German Many

Listen to this 2-hour webinar presented on April 22, 2021 to learn about global topics related to bleeding disorders. The

Adapted from: Global NMO Training 2018 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael The

Adapted from: Global NMO Training 2016 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael This

In the Monday morning session entitled Inhibitors: Clinical Aspects, Henry Daniell presents current advances in the development of new, affordable